Distinguished in Acute Myeloid Leukemia (AML)

David Cuadron-Martinez

Avda. Fernando Abril Martorell 106, CP, 
Valencia, VC, ES 
Distinguished in Acute Myeloid Leukemia (AML)
Avda. Fernando Abril Martorell 106, CP, 
Valencia, VC, ES 
OverviewLocationsClinical Research

Overview

David Cuadron-Martinez practices in Valencia, Spain. Mr. Cuadron-Martinez is rated as a Distinguished expert by MediFind in the treatment of Acute Myeloid Leukemia (AML). His top areas of expertise are Acute Myeloid Leukemia (AML), Leukemia, Acute Promyelocytic Leukemia, Leukocytosis, and Bone Marrow Transplant.

His clinical research consists of co-authoring 110 peer reviewed articles and participating in 1 clinical trial. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 96 articles and participated in 1 clinical trial in the study of Acute Myeloid Leukemia (AML).

Gender
Male

Locations

Avda. Fernando Abril Martorell 106, CP, Valencia, VC 46026, Spain

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

A 2:1 Randomized Phase II Trial to Compare the Efficacy and Safety of Standard Chemotherapy Plus Quizartinib Versus Standard Chemotherapy Plus Placebo in Adult Patients With Newly Diagnosed FLT3 Wild-type AML
A 2:1 Randomized Phase II Trial to Compare the Efficacy and Safety of Standard Chemotherapy Plus Quizartinib Versus Standard Chemotherapy Plus Placebo in Adult Patients With Newly Diagnosed FLT3 Wild-type AML
Enrollment Status: Completed
Publish Date: September 02, 2025
Intervention Type: Drug
Study Drugs: Quizartinib, Cytarabine, Idarubicin
Study Phase: Phase 2

110 Total Publications

Quizartinib for Newly Diagnosed FLT3-ITD-Negative Acute Myeloid Leukemia: The Randomized, Double-Blind, Placebo-Controlled, Phase 2 QUIWI Study.
Quizartinib for Newly Diagnosed FLT3-ITD-Negative Acute Myeloid Leukemia: The Randomized, Double-Blind, Placebo-Controlled, Phase 2 QUIWI Study.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: October 13, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Cuadron-Martinez's expertise for a condition
ConditionClose
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile